Patient preferences in targeted pharmacotherapy for cancers: A systematic review of discrete choice experiments

Shan Jiang, Ru Ren, Yuanyuan Gu*, Varinder Jeet, Ping Liu, Shunping Li

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)
49 Downloads (Pure)

Abstract

Background: Targeted pharmacotherapy has been increasingly applied in cancer treatment due to its breakthroughs. However, the unmet needs of cancer patients are still significant, highlighting the urgency to investigate patient preferences. It is unclear how patients deliberate their choices between different aspects of targeted therapy, including cost, efficacy, and adverse events. Since discrete choice experiments (DCEs) have been widely applied to patient preference elicitation, we reviewed DCEs on targeted therapy for different cancers. We also synthesized evidence on the factors influencing patients’ choices and their willingness-to-pay (WTP) for survival when treated by targeted therapy.

Methods: We searched databases, including PubMed, EMBASE and MEDLINE, up to August 16, 2022, supplemented by a reference screening. The attributes from the selected studies were categorized into three groups: outcomes, costs, and process. We also calculated the relative importance of attributes and WTP for survival whenever possible. The purpose, respondents, explanation, findings, significance (PREFS) checklist was used to evaluate the quality of the included DCE studies.

Results: The review identified 34 eligible studies from 13 countries covering 14 cancers, such as breast, ovarian, kidney, prostate, and skin cancers. It also reveals a rising trend of DCEs on this topic, as most studies were published after 2018. We found that patients placed higher weights on the outcome (e.g., overall survival) and cost attributes than on process attributes. On average, patients were willing to pay $561 (95% confidence interval [CI]: $415–$758) and $716 (95% CI $524–$958) out-of-pocket for a 1-month increase in progression-free survival and overall survival, respectively. PREFS scores of the 34 studies ranged from 2 to 4, with a mean of 3.38 (SD: 0.65), suggesting a reasonable quality based on the checklist. However, most studies (n = 32, 94%) did not assess the impact of non-responses on the results.

Conclusions: This is the first systematic review focusing on patient preferences for targeted cancer therapy. We showcased novel approaches for evidence synthesis of DCE results, especially the attribute relative importance and WTP. The results may inform stakeholders about patient preferences toward targeted therapy and their WTP estimates. More studies with improved study design and quality are warranted to generate more robust evidence to assist decision making.
Original languageEnglish
Pages (from-to)43-57
Number of pages15
JournalPharmacoEconomics
Volume41
Issue number1
Early online date14 Nov 2022
DOIs
Publication statusPublished - Jan 2023

Fingerprint

Dive into the research topics of 'Patient preferences in targeted pharmacotherapy for cancers: A systematic review of discrete choice experiments'. Together they form a unique fingerprint.

Cite this